Displaying 41 - 50 of 243
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Chongqing Medical Equipment Factory Co., Ltd.
Development Stage: Marketed
Development Phase: Limited Market Availability
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Other
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
Alternative Name: Inhibition of Vas Propulsive Contractility
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: King's College, London
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
User: Female
Hormonal: Yes
Delivery Method: Transdermal
Developer: Viramal Limited
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel, Vaginal, Other
Developer: Central Drug Research Institute, India, HLL Lifecare Limited
Development Stage: Regulatory
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: BioRings Intravaginal Ring
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: BioRings, Weill Cornell Medical College, QPharma
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Carboxy Terminus Peptide of β-human chorionic gonadotropin
User: Female
Hormonal: No
Developer: WHO, Talwar Research Foundation
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Nanocomposite Copper (Cu) IUD
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Tongji Medical College at Huazhong University of Science and Technology
Development Stage: Marketed
Development Phase: Limited Market Availability
Alternative Name: l'Amour®; Jeitosa®
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Cupid Ltd.
Development Stage: SRA/WHO PQ Approved
Development Phase: Limited Market Availability
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Cupid Ltd.
Development Phase: Limited Market Availability

Pages

Displaying 11 - 20 of 70
Alternative Name: ATPase Plasma Membrane Calcium Transporting 4, PMCA4, Plasma Membrane Calcium-Transporting ATPase 4, PMCA4b, PMCA4x, Matrix-Remodeling-Associated Protein 1, Sarcolemmal Calcium Pump, EC 7.2.2.10, EC 3.6.3.8, EC 3.6.3
Target
User: Female, Male
Hormonal: No
Development Stage: Target Identification
User: Male
Hormonal: No
Delivery Method: Oral
Developer: Norfolk State University
Development Stage: Lead Optimization
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal, Other
Developer: University of Cincinnati
Development Stage: Lead Optimization
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Subdermal
Developer: Murdoch University
Development Stage: Prototype Development
Alternative Name: Bromodomain Testis Associated, Cancer/Testis Antigen 9, Bromodomain Testis-Specific Protein, Bromodomain, Testis-Specific, RING3-Like Protein, CT9, SPGF21, BRD6
Target
User: Male
Hormonal: No
Delivery Method: Injectable, Oral
Development Stage: Lead Optimization
User: Male
Hormonal: No
Delivery Method: Oral
Developer: Bar-Ilan University
Development Stage: Compound ID/Selection
Alternative Name: Calcium Binding Tyrosine Phosphorylation Regulated, Cancer/Testis Antigen 88, Calcium-Binding Tyrosine Phosphorylation-Regulated Protein, Testis-Specific Calcium-Binding Protein CBP86, Calcium-Binding Protein 86, Fibrousheathin II, Fibrousheathin-2, CBP86, FSP-2, CT88, FSP2
Target
User: Female, Male
Hormonal: No
Development Stage: Target Validation
Alternative Name: Calrecticulin 3, Calsperin, Cancer/Testis Antigen 93, Calreticulin-2, CRT2, Testis Secretory Sperm-Binding Protein Li 226n, CMH19, CT93
Target
User: Male
Hormonal: No
Development Stage: Target Validation
Target
User: Female, Male
Hormonal: No
Duration Type: Short-acting, Pericoital, Emergency
Developer: Hydra Biosciences, University of Minnesota, University of California at Berkeley, Harvard University, Dare BioScience Inc.
Development Stage: Lead Optimization
Alternative Name: Cyclin-dependent kinases (CDKs)
Target
User: Male
Hormonal: Yes
Developer: University of Kansas Medical Center, University of Minnesota, Moffitt Cancer Center at University of South Florida
Development Stage: Target Identification

Pages

Displaying 1 - 10 of 121
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shandong Provincial Institute, China, Technology for Family Planning, China
Development Stage: Pre-clinical
Alternative Name: Inhibitors of Testicular Retinoic Acid Biosynthesis
User: Male
Hormonal: No
Duration Type: Long-acting, Short-acting
Delivery Method: Oral
Developer: University of Washington, University of Minnesota
Development Stage: Pre-clinical
Alternative Name: ARC; triple hormone contraceptive; Triple OC
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: ANI Pharmaceuticals, Pantarhei Bioscience
Development Stage: Phase II
Alternative Name: Suspensories
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Testicular
Developer: Centre Hospitalier Universitaire de Toulouse, France
Development Stage: Phase II
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: FHI 360, Yale University
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Peking University, Institute of Biomedical Engineering at Chinese Academy of Medical College
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR)
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: University of Washington
Development Stage: Pre-clinical
Alternative Name: BDADs
User: Female, Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: Focused Scientific, University of Washington
Development Stage: Pre-clinical
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal Gel
Developer: ReProtect Inc.
Development Stage: Phase III

Pages

Displaying 11 - 20 of 52
User: Female
Hormonal: Yes
Duration Type: Emergency
Delivery Method: Oral
Developer: HRA Pharma
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Pregna International Limited
Development Stage: Marketed
Alternative Name: ENG + EE Vaginal Ring
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Amneal
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: HLL Lifecare Limited, Sree Chitra Tirunal Institute for Medical Sciences & Technology (SCTIMST)
Development Stage: Marketed
Alternative Name: Gold T IUD; Novaplus T 380 Ag IUD; Novaplus T 380 Cu IUD; Ancora 375 Ag IUD; Ancora 375 Cu IUD; Ancora 250 Cu Mini IUD
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Eurogine
Development Stage: Marketed
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Famy Care Ltd.
Development Stage: Marketed
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium, APCOR R&M, Belgium
Development Stage: Regulatory
Alternative Name: Fibroplant LNG14 (also LNG 20)
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Development Stage: Regulatory
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Meril Life Science Private Ltd
Development Stage: Marketed
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Prosan International B.V.
Development Stage: Marketed

Pages

CSV